Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi-Long Lung Cancer Wu, Martin Schüler et al. · The Lancet Oncology · 2015

Cited by 1,571 works. doi:10.1016/s1470-2045(14)71173-8 Open-access PDF

Authors

References